prednisolone has been researched along with Precursor B-Cell Lymphoblastic Leukemia-Lymphoma in 24 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma: A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Careful monitoring for recurrence or a third malignancy is needed." | 2.44 | Parotid acinar cell carcinoma in a long-term survivor of childhood acute lymphoblastic leukemia. ( Chan, GC; Cheuk, DK; Chiang, AK; Ha, SY; Lau, YL; Shek, TW, 2008) |
| "Even though acute lymphoblastic leukemia (ALL) responds well to chemotherapy, relapse remains the major problem." | 2.41 | Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy. ( Botsonis, A; Moschovi, M; Papadopoulou, AL; Tsangaris, GT; Tzortzatou-Stathopoulou, F, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (12.50) | 18.2507 |
| 2000's | 7 (29.17) | 29.6817 |
| 2010's | 13 (54.17) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Ishida, H | 1 |
| Yano, M | 1 |
| Hasegawa, D | 2 |
| Hori, T | 2 |
| Hashii, Y | 2 |
| Kato, K | 3 |
| Deguchi, T | 2 |
| Saito, A | 1 |
| Sato, A | 2 |
| Hori, H | 3 |
| Horibe, K | 3 |
| Imamura, T | 2 |
| Usami, I | 2 |
| Takahashi, Y | 1 |
| Suenobu, SI | 1 |
| Shimada, A | 1 |
| Ito, E | 1 |
| Moriya-Saito, A | 1 |
| Kawasaki, H | 1 |
| Yumura-Yagi, K | 2 |
| Hara, J | 2 |
| van Zelm, MC | 1 |
| Pumar, M | 1 |
| Shuttleworth, P | 1 |
| Aui, PM | 1 |
| Smart, JM | 1 |
| Grigg, A | 1 |
| Bosco, JJ | 1 |
| Wong, NC | 1 |
| Bhadri, VA | 1 |
| Maksimovic, J | 1 |
| Parkinson-Bates, M | 1 |
| Ng, J | 1 |
| Craig, JM | 1 |
| Saffery, R | 1 |
| Lock, RB | 1 |
| Junk, S | 1 |
| Cario, G | 1 |
| Wittner, N | 1 |
| Stanulla, M | 2 |
| Scherer, R | 1 |
| Schlegelberger, B | 1 |
| Schrappe, M | 2 |
| von Neuhoff, N | 1 |
| Lauten, M | 2 |
| Polak, R | 1 |
| de Rooij, B | 1 |
| Pieters, R | 3 |
| den Boer, ML | 1 |
| Marke, R | 1 |
| Havinga, J | 1 |
| Cloos, J | 1 |
| Demkes, M | 1 |
| Poelmans, G | 1 |
| Yuniati, L | 1 |
| van Ingen Schenau, D | 1 |
| Sonneveld, E | 1 |
| Waanders, E | 1 |
| Kuiper, RP | 1 |
| Hoogerbrugge, PM | 1 |
| Kaspers, GJ | 1 |
| van Leeuwen, FN | 1 |
| Scheijen, B | 1 |
| Thakral, B | 1 |
| Khoury, JD | 1 |
| Kalantri, SA | 1 |
| Datta, S | 1 |
| Maitra, D | 1 |
| Bhattacharyya, M | 1 |
| Ouimet, M | 1 |
| Drouin, S | 1 |
| Lajoie, M | 1 |
| Caron, M | 1 |
| St-Onge, P | 1 |
| Gioia, R | 1 |
| Richer, C | 1 |
| Sinnett, D | 1 |
| Kudoh, T | 1 |
| Nishimura, S | 1 |
| Oda, M | 2 |
| Yoshida, M | 1 |
| Komada, Y | 1 |
| Tawa, A | 1 |
| Tanizawa, A | 1 |
| Kobayashi, R | 2 |
| Matsuo, K | 1 |
| Yang, JJ | 1 |
| Bhojwani, D | 1 |
| Yang, W | 1 |
| Cai, X | 1 |
| Stocco, G | 1 |
| Crews, K | 1 |
| Wang, J | 1 |
| Morrison, D | 1 |
| Devidas, M | 1 |
| Hunger, SP | 1 |
| Willman, CL | 1 |
| Raetz, EA | 1 |
| Pui, CH | 1 |
| Evans, WE | 1 |
| Relling, MV | 1 |
| Carroll, WL | 1 |
| Nishikawa, T | 1 |
| Kawakami, K | 1 |
| Kumamoto, T | 1 |
| Tonooka, S | 1 |
| Abe, A | 1 |
| Hayasaka, K | 1 |
| Okamoto, Y | 1 |
| Kawano, Y | 1 |
| Malbora, B | 1 |
| Ozyurek, E | 1 |
| Kocum, AI | 1 |
| Ozbek, N | 1 |
| Morishita, N | 1 |
| Tsukahara, H | 1 |
| Chayama, K | 1 |
| Ishida, T | 1 |
| Washio, K | 1 |
| Miyamura, T | 1 |
| Yamashita, N | 1 |
| Morishima, T | 1 |
| Möricke, A | 1 |
| Beier, R | 1 |
| Zimmermann, M | 1 |
| Meissner, B | 1 |
| Odenwald, E | 1 |
| Attarbaschi, A | 1 |
| Niemeyer, C | 1 |
| Niggli, F | 1 |
| Riehm, H | 1 |
| Takanashi, K | 1 |
| Suzuki, D | 1 |
| Nasu, T | 1 |
| Uetake, K | 1 |
| Matsumoto, Y | 1 |
| Cheuk, DK | 1 |
| Shek, TW | 1 |
| Chan, GC | 1 |
| Lau, YL | 1 |
| Ha, SY | 1 |
| Chiang, AK | 1 |
| Steiner, I | 1 |
| Aebi, C | 1 |
| Ridolfi Lüthy, A | 1 |
| Wagner, B | 1 |
| Leibundgut, K | 1 |
| Soslow, RA | 1 |
| Davis, RE | 1 |
| Warnke, RA | 1 |
| Cleary, ML | 1 |
| Kamel, OW | 1 |
| Gillies, J | 1 |
| Hung, KA | 1 |
| Fitzsimons, E | 1 |
| Soutar, R | 1 |
| Bueno, J | 1 |
| Zuazu, J | 1 |
| Villalba, T | 1 |
| Julià, A | 1 |
| Styczynski, J | 1 |
| Huismans, DR | 1 |
| Schuurhuis, GJ | 1 |
| Wysocki, M | 1 |
| Veerman, AJ | 1 |
| Tzortzatou-Stathopoulou, F | 1 |
| Papadopoulou, AL | 1 |
| Moschovi, M | 1 |
| Botsonis, A | 1 |
| Tsangaris, GT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia[NCT00137111] | Phase 3 | 501 participants (Actual) | Interventional | 2000-07-08 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"White blood cell (leukocytes) counts in peripheral blood by Complete Blood Count~Measurement: Percentage change of leukemia cells from baseline" (NCT00137111)
Timeframe: Immediately before the methotrexate infusion and three days after subsequent infusion
| Intervention | Percent change (Mean) |
|---|---|
| 4 hr | -44 |
| 24 hr | -50 |
CCR was measured from end of week 56 therapy to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow up time (range) 4.5 (1 to 7.8) years
| Intervention | Percentage of participants (Number) |
|---|---|
| Patients With High Risk of CNS Relapse | 92.2 |
Children were randomly assigned to receive initial single-agent treatment with HDMTX (1g/m^2) as either a 24-hour infusion or a 4-hour infusion and the outcome measure was the accumulation of MTXPG in leukemia cells. (NCT00137111)
Timeframe: 42 hours after start of high dose methotrexate infusion (HDMTX)
| Intervention | pmol/1,000,000,000 cells (Mean) |
|---|---|
| 4 hr | 1688 |
| 24 hr | 2521 |
EFS was measured from the start of on-study to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Failure to enter remission was considered an event at time zero. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow-up time (range) 5.6 (1.3 to 8.9) years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Total Therapy | 87.3 |
Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of CASP1 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment
| Intervention | arbitrary units (Median) | |
|---|---|---|
| Prednisolone-sensitive cells | Prednisolone-resistant cells | |
| Total Therapy | 341.3 | 447.9 |
Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of NLRP3 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment
| Intervention | arbitrary units (Median) | |
|---|---|---|
| Prednisolone-sensitive cells | Prednisolone-resistant cells | |
| Total Therapy | 41.2 | 110.7 |
Detection of MRD at end of induction where positive MRD was defined as one or more leukemic cell per 10,000 mononuclear bone-marrow cells (>=0.01%). (NCT00137111)
Timeframe: End of Induction (Day 46 MRD measurement)
| Intervention | participants (Number) | |
|---|---|---|
| Negative <0.01% | Positive >= 0.01% | |
| Total Therapy | 390 | 102 |
2 reviews available for prednisolone and Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Parotid acinar cell carcinoma in a long-term survivor of childhood acute lymphoblastic leukemia.
Topics: Adenoma, Sweat Gland; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Carcinoma, Acina | 2008 |
Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Bone Marrow T | 2001 |
4 trials available for prednisolone and Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Prednisolone poor response is not an indication for HSCT in pediatric B-cell precursor acute lymphoblastic leukemia in first remission: results from JACLS ALL-02 study.
Topics: Adolescent; Allografts; Child; Child, Preschool; Disease-Free Survival; Female; Hematopoietic Stem C | 2021 |
Long-term Results of the Risk-adapted Treatment for Childhood B-Cell Acute Lymphoblastic Leukemia: Report From the Japan Association of Childhood Leukemia Study ALL-97 Trial.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2017 |
Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B-precursor acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transpor | 2012 |
Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers; Bone Marrow; Child; Child, | 2012 |
18 other studies available for prednisolone and Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Discontinuation of L-asparaginase and poor response to prednisolone are associated with poor outcome of ETV6-RUNX1-positive pediatric B-cell precursor acute lymphoblastic leukemia.
Topics: Asparaginase; Child; Child, Preschool; Core Binding Factor Alpha 2 Subunit; Disease-Free Survival; F | 2019 |
Functional Antibody Responses Following Allogeneic Stem Cell Transplantation for
Topics: Adult; Agammaglobulinemia; Cyclosporine; Genetic Diseases, X-Linked; Graft vs Host Disease; Hematopo | 2019 |
Stability of gene expression and epigenetic profiles highlights the utility of patient-derived paediatric acute lymphoblastic leukaemia xenografts for investigating molecular mechanisms of drug resistance.
Topics: Adolescent; Animals; Antineoplastic Agents, Hormonal; Child; Disease Models, Animal; DNA Methylation | 2014 |
Bortezomib Treatment can Overcome Glucocorticoid Resistance in Childhood B-cell Precursor Acute Lymphoblastic Leukemia Cell Lines.
Topics: Adenosine Triphosphatases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bortezomib; Ce | 2015 |
B-cell precursor acute lymphoblastic leukemia cells use tunneling nanotubes to orchestrate their microenvironment.
Topics: Adolescent; Cell Communication; Cell Line, Tumor; Child; Child, Preschool; Cytokines; Drug Resistanc | 2015 |
Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia.
Topics: Animals; Dexamethasone; Drug Resistance, Neoplasm; Genotype; Glucocorticoids; Humans; Ikaros Transcr | 2016 |
Histiocytic sarcoma: secondary neoplasm or "transdifferentiation" in the setting of B-acute lymphoblastic leukemia.
Topics: Adult; Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Female; GTP Phosphoh | 2016 |
Thyroid abscess in case of Pre B acute lymphoblastic leukaemia: a rare presentation.
Topics: Abscess; Adolescent; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Clindamy | 2016 |
A childhood acute lymphoblastic leukemia-specific lncRNA implicated in prednisolone resistance, cell proliferation, and migration.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; | 2017 |
Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Child; Child, Preschoo | 2008 |
Severe neurotoxicities in a case of Charcot-Marie-Tooth disease type 2 caused by vincristine for acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aspar | 2008 |
Delayed recognition of intrathecal methotrexate overdose.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothera | 2009 |
Retinitis from cytomegalovirus during maintenance treatment for acute lymphoblastic leukemia.
Topics: Antimetabolites, Antineoplastic; Antiviral Agents; Child; Cytomegalovirus Retinitis; Drug Therapy, C | 2012 |
Fatal adenovirus hepatitis during maintenance therapy for childhood acute lymphoblastic leukemia.
Topics: Adenovirus Infections, Human; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Aspa | 2008 |
True histiocytic lymphoma following therapy for lymphoblastic neoplasms.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Neoplasms; Child; Cisplati | 1996 |
Severe vincristine toxicity in combination with itraconazole.
Topics: Adult; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Aspergillosi | 1998 |
[Acute leukemia in Jehovah's Witnesses].
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blood Transfusion; Chri | 1999 |
In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Asparaginase; Bone Marrow Cells; Child; Child | 2000 |